Cargando…

Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas

INTRODUCTION: Human epidermal growth factor receptor (HER)-2 overexpression or gene amplification is more common in high-grade or type 2 endometrial carcinomas. We assessed the discordance of HER-2 expression between primary and metastatic or recurrent endometrial carcinomas. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Rina, Hasegawa, Kiyoshi, Ishii, Risa, Owaki, Akiko, Torii, Yutaka, Oe, Shuko, Hirasawa, Hiroshi, Kobayashi, Yoichi, Udagawa, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742156/
https://www.ncbi.nlm.nih.gov/pubmed/23950654
http://dx.doi.org/10.2147/OTT.S47504
_version_ 1782280322123038720
author Kato, Rina
Hasegawa, Kiyoshi
Ishii, Risa
Owaki, Akiko
Torii, Yutaka
Oe, Shuko
Hirasawa, Hiroshi
Kobayashi, Yoichi
Udagawa, Yasuhiro
author_facet Kato, Rina
Hasegawa, Kiyoshi
Ishii, Risa
Owaki, Akiko
Torii, Yutaka
Oe, Shuko
Hirasawa, Hiroshi
Kobayashi, Yoichi
Udagawa, Yasuhiro
author_sort Kato, Rina
collection PubMed
description INTRODUCTION: Human epidermal growth factor receptor (HER)-2 overexpression or gene amplification is more common in high-grade or type 2 endometrial carcinomas. We assessed the discordance of HER-2 expression between primary and metastatic or recurrent endometrial carcinomas. MATERIALS AND METHODS: Thirty-six primary, along with 14 metastatic and five recurrent tumors (matched to primaries), pathologically confirmed as high-grade or type 2 endometrial carcinomas, were submitted for immunohistochemistry (IHC) for HER-2. Fluorescence in situ hybridization was performed when the tumors showed HER-2 overexpression (≥2+ IHC score). The results of the IHC and fluorescence in situ hybridization assays were compared between the primary and metastatic or recurrent tumors. The relationships between HER-2 expression and clinicopathological factors or prognosis were investigated. RESULTS: HER-2 overexpression and HER-2 amplification (a ratio of HER-2 copies to chromosome 17 [CEP17] copies ≥2.2) were detected in 33.3% (twelve of 36 patients) and 5.6% (two of 36 patients) of primary tumors, respectively. HER-2 overexpression was not associated with clinicopathological factors or prognosis. In 19 tumor specimens obtained from metastatic or recurrent tumors, HER-2 overexpression and HER-2 amplification were detected in 57.9% (eleven patients) and 15.8% (three patients), respectively. HER-2 overexpression tended to predict a worse prognosis. CONCLUSION: HER-2 expression in metastatic or recurrent tumors was more frequent than in matched primary high-grade or type 2 endometrial carcinomas. Trastuzumab in combination with cytotoxic chemotherapy may represent an alternative therapeutic option for these tumors.
format Online
Article
Text
id pubmed-3742156
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37421562013-08-15 Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas Kato, Rina Hasegawa, Kiyoshi Ishii, Risa Owaki, Akiko Torii, Yutaka Oe, Shuko Hirasawa, Hiroshi Kobayashi, Yoichi Udagawa, Yasuhiro Onco Targets Ther Original Research INTRODUCTION: Human epidermal growth factor receptor (HER)-2 overexpression or gene amplification is more common in high-grade or type 2 endometrial carcinomas. We assessed the discordance of HER-2 expression between primary and metastatic or recurrent endometrial carcinomas. MATERIALS AND METHODS: Thirty-six primary, along with 14 metastatic and five recurrent tumors (matched to primaries), pathologically confirmed as high-grade or type 2 endometrial carcinomas, were submitted for immunohistochemistry (IHC) for HER-2. Fluorescence in situ hybridization was performed when the tumors showed HER-2 overexpression (≥2+ IHC score). The results of the IHC and fluorescence in situ hybridization assays were compared between the primary and metastatic or recurrent tumors. The relationships between HER-2 expression and clinicopathological factors or prognosis were investigated. RESULTS: HER-2 overexpression and HER-2 amplification (a ratio of HER-2 copies to chromosome 17 [CEP17] copies ≥2.2) were detected in 33.3% (twelve of 36 patients) and 5.6% (two of 36 patients) of primary tumors, respectively. HER-2 overexpression was not associated with clinicopathological factors or prognosis. In 19 tumor specimens obtained from metastatic or recurrent tumors, HER-2 overexpression and HER-2 amplification were detected in 57.9% (eleven patients) and 15.8% (three patients), respectively. HER-2 overexpression tended to predict a worse prognosis. CONCLUSION: HER-2 expression in metastatic or recurrent tumors was more frequent than in matched primary high-grade or type 2 endometrial carcinomas. Trastuzumab in combination with cytotoxic chemotherapy may represent an alternative therapeutic option for these tumors. Dove Medical Press 2013-08-07 /pmc/articles/PMC3742156/ /pubmed/23950654 http://dx.doi.org/10.2147/OTT.S47504 Text en © 2013 Kato et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Kato, Rina
Hasegawa, Kiyoshi
Ishii, Risa
Owaki, Akiko
Torii, Yutaka
Oe, Shuko
Hirasawa, Hiroshi
Kobayashi, Yoichi
Udagawa, Yasuhiro
Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas
title Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas
title_full Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas
title_fullStr Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas
title_full_unstemmed Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas
title_short Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas
title_sort human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742156/
https://www.ncbi.nlm.nih.gov/pubmed/23950654
http://dx.doi.org/10.2147/OTT.S47504
work_keys_str_mv AT katorina humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas
AT hasegawakiyoshi humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas
AT ishiirisa humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas
AT owakiakiko humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas
AT toriiyutaka humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas
AT oeshuko humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas
AT hirasawahiroshi humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas
AT kobayashiyoichi humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas
AT udagawayasuhiro humanepidermalgrowthfactorreceptor2overexpressionandamplificationinmetastaticandrecurrenthighgradeortype2endometrialcarcinomas